JP2024518011A5 - - Google Patents
Info
- Publication number
- JP2024518011A5 JP2024518011A5 JP2023551146A JP2023551146A JP2024518011A5 JP 2024518011 A5 JP2024518011 A5 JP 2024518011A5 JP 2023551146 A JP2023551146 A JP 2023551146A JP 2023551146 A JP2023551146 A JP 2023551146A JP 2024518011 A5 JP2024518011 A5 JP 2024518011A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen
- receptor
- mam
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163151421P | 2021-02-19 | 2021-02-19 | |
| US63/151,421 | 2021-02-19 | ||
| US202163245181P | 2021-09-16 | 2021-09-16 | |
| US63/245,181 | 2021-09-16 | ||
| PCT/US2022/017177 WO2022178367A2 (en) | 2021-02-19 | 2022-02-21 | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518011A JP2024518011A (ja) | 2024-04-24 |
| JP2024518011A5 true JP2024518011A5 (cg-RX-API-DMAC7.html) | 2025-04-10 |
Family
ID=82932320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551146A Pending JP2024518011A (ja) | 2021-02-19 | 2022-02-21 | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240390496A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4297769A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024518011A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230153529A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022224066A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208717A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305175A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022178367A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| KR20220149606A (ko) * | 2020-03-02 | 2022-11-08 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료를 위한 키메라 항원 수용체 및 관련 방법 및 조성물 |
| WO2021188599A1 (en) * | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| AR130387A1 (es) * | 2022-09-08 | 2024-12-04 | Hoffmann La Roche | Receptores de linfocitos t recombinantes |
| CN116514992B (zh) * | 2022-11-07 | 2024-05-24 | 武汉波睿达生物科技有限公司 | 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用 |
| WO2024102954A1 (en) * | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| JP2026501516A (ja) * | 2023-01-05 | 2026-01-16 | アンヘレス セラピューティクス インコーポレイテッド | 遺伝子導入および合成および免疫受容体の活性を制御するための方法および組成物 |
| SE548109C2 (en) * | 2023-03-28 | 2026-03-30 | Cerimmune Therapeutics Ab | Microglial endocytic receptors for use in the treatment of neurodegenerative disease |
| PE20260290A1 (es) * | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| CN121620592A (zh) * | 2023-05-01 | 2026-03-06 | 西雅图儿童医院d/b/a西雅图儿童研究所 | 表达突变体白细胞介素15的免疫细胞 |
| EP4712986A1 (en) * | 2023-05-18 | 2026-03-25 | A2 Biotherapeutics, Inc. | Immune cells with paired receptors and uses thereof |
| JP2026526219A (ja) * | 2023-07-28 | 2026-08-06 | エヌケーアイエルティー セラピューティクス インコーポレイテッド | キメラilt受容体組成物および方法 |
| WO2025067318A1 (zh) * | 2023-09-28 | 2025-04-03 | 沛尔生技医药股份有限公司 | 具有细胞内信号传导结构域及自然杀伤蛋白30跨膜结构域的核酸分子及包含其的嵌合抗原受体 |
| WO2025193475A1 (en) * | 2024-03-14 | 2025-09-18 | The Regents Of The University Of California | Enhancing immune cell innate and adaptive responses |
| WO2025194049A1 (en) * | 2024-03-15 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Engineered immune cells and methods of using the same |
| WO2025235862A1 (en) * | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| TW202617750A (zh) * | 2024-07-10 | 2026-05-01 | 美商安吉利斯治療學公司 | 包含表位與多肽的組成物及方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1131425A2 (en) * | 1998-11-18 | 2001-09-12 | Incyte Pharmaceuticals, Inc. | Inflammation-associated genes |
| EP1882392A4 (en) * | 2005-05-10 | 2009-07-01 | Monsanto Technology Llc | GENES AND THEIR USES FOR PLANT IMPROVEMENTS |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| US10093701B2 (en) * | 2012-09-07 | 2018-10-09 | University Of Miami | Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof |
| CA2912375C (en) * | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| SI2997141T1 (sl) * | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| CN114533867A (zh) * | 2015-03-27 | 2022-05-27 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| EP3390645B1 (en) * | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| CN108728465A (zh) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用 |
| SG11202008568WA (en) * | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
| KR102907902B1 (ko) * | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
-
2022
- 2022-02-21 IL IL305175A patent/IL305175A/en unknown
- 2022-02-21 US US18/275,957 patent/US20240390496A1/en active Pending
- 2022-02-21 EP EP22757078.5A patent/EP4297769A4/en active Pending
- 2022-02-21 CA CA3208717A patent/CA3208717A1/en active Pending
- 2022-02-21 WO PCT/US2022/017177 patent/WO2022178367A2/en not_active Ceased
- 2022-02-21 AU AU2022224066A patent/AU2022224066A1/en active Pending
- 2022-02-21 KR KR1020237031803A patent/KR20230153529A/ko active Pending
- 2022-02-21 JP JP2023551146A patent/JP2024518011A/ja active Pending